AI-driven drug discovery is limited not by compute or models, but by a critical data gap—models learn from success while missing the far richer signals hidden in biological failure.

Biobanks are evolving from static sample repositories into AI-powered, dynamic intelligence platforms that transform real-world data into actionable insights for faster, smarter healthcare innovation.

How AI can connect scattered patient data to deliver faster, more accurate treatment.

From fragmented AI tools to clinically grounded intelligence — healthcare is entering its foundation model era.

Decoding AI maturity in life sciences—from silos to self-learning ecosystems.

Turning decades of fragmented health data into intelligent, real-time insights for better care and faster discovery

An in-depth look at how capital, innovation, and strategic collaborations are driving the next wave of breakthroughs in CNS and neurodegenerative disease research.

Strategic AI/ML Interventions Aligned to the 2026 Rare Disease Strategic Agenda from FDA Rare Disease Innovation Hub.

2026 is redefining obesity treatment—moving from weight loss alone to oral therapies, muscle preservation, and long-term metabolic health.

2026 will be a pivotal year for drug development—read our latest white paper to explore the late-stage clinical trial readouts set to reshape medicine and markets.

China is no longer just in the pharma race — it’s helping define where global innovation comes from.

2026 marks biotech’s shift to precision cures—removing disease proteins, retraining biology, and targeting delivery to unlock safer, more durable therapies and long-term clinical leadership.

2025 emerged as a pivotal year for rare-disease dealmaking, driven by advanced biologics, strategic licensing, and strong unmet medical needs.

Big Pharma M&As are driven by premium platform technologies, neurology, oncology and obesity bets and near-term readouts that will validate the deals.

Oncology remains the undisputed leader in global dealmaking for 2025, fueled by relentless demand for differentiated therapies and next-generation modalities

Innoplexus’ CTP model forecasts the outcome of clinical studies and may serve as an early indicator for future stock movements.

Emergence of chimeric antigen receptor-t (CAR-T) cell therapies for cancer treatment

Gene therapy promises to hold the cure to a number of diseases which, until now, have been considered incurable. Read our recent whitepaper